American Century Companies Inc. Boosts Holdings in IQVIA Holdings Inc. (NYSE:IQV)

American Century Companies Inc. grew its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 26.8% during the first quarter, HoldingsChannel reports. The firm owned 1,438,995 shares of the medical research company’s stock after buying an additional 304,258 shares during the period. American Century Companies Inc.’s holdings in IQVIA were worth $253,695,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Ethic Inc. increased its holdings in IQVIA by 8.9% during the 1st quarter. Ethic Inc. now owns 23,893 shares of the medical research company’s stock worth $4,092,000 after purchasing an additional 1,947 shares during the last quarter. Aberdeen Group plc increased its holdings in IQVIA by 91.5% during the 1st quarter. Aberdeen Group plc now owns 137,843 shares of the medical research company’s stock worth $23,856,000 after purchasing an additional 65,878 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in IQVIA by 2.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,428,561 shares of the medical research company’s stock worth $251,852,000 after purchasing an additional 40,699 shares during the last quarter. Providence Capital Advisors LLC increased its holdings in IQVIA by 2.3% during the 1st quarter. Providence Capital Advisors LLC now owns 22,771 shares of the medical research company’s stock worth $4,015,000 after purchasing an additional 507 shares during the last quarter. Finally, Kovitz Investment Group Partners LLC increased its holdings in IQVIA by 658.8% during the 1st quarter. Kovitz Investment Group Partners LLC now owns 28,774 shares of the medical research company’s stock worth $5,073,000 after purchasing an additional 24,982 shares during the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on IQV. Mizuho lifted their target price on IQVIA from $190.00 to $225.00 and gave the stock an “outperform” rating in a research report on Friday, July 25th. Evercore ISI lifted their target price on IQVIA from $170.00 to $180.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 9th. JPMorgan Chase & Co. decreased their target price on IQVIA from $232.00 to $177.00 and set an “overweight” rating for the company in a research report on Monday, May 19th. Truist Financial lifted their target price on IQVIA from $209.00 to $235.00 and gave the stock a “buy” rating in a research report on Wednesday, July 23rd. Finally, Cowen restated a “buy” rating on shares of IQVIA in a research report on Wednesday, July 23rd. Seven research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus target price of $228.62.

Insider Buying and Selling

In other news, insider Keriann Cherofsky sold 549 shares of the stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the transaction, the insider directly owned 2,910 shares of the company’s stock, valued at approximately $557,352.30. This represents a 15.87% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Eric Sherbet sold 5,800 shares of the firm’s stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the sale, the insider directly owned 27,178 shares of the company’s stock, valued at $5,165,178.90. This represents a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company’s stock.

IQVIA Price Performance

Shares of NYSE:IQV opened at $189.50 on Friday. The business has a 50 day moving average price of $169.61 and a 200 day moving average price of $168.92. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $252.88. The company has a market cap of $32.21 billion, a price-to-earnings ratio of 27.42, a PEG ratio of 2.09 and a beta of 1.30. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%. The company had revenue of $4.02 billion during the quarter, compared to the consensus estimate of $3.96 billion. During the same quarter last year, the company earned $2.64 EPS. The company’s quarterly revenue was up 5.3% on a year-over-year basis. Research analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.